Lena Winestone, MD

Assistant Professor
School of Medicine
550 16th. Street
San Francisco, CA 94158
profile placeholder UCSF logo
Education and Training

University of Pennsylvania, , BA - 2004 Biochemistry

Stanford University School of Medicine, , MD - 2009 Medicine

Lucile Packard Children's Hospital, , Residency - 2012 Pediatrics

Perelman School of Medicine, University of Pennsylvania, , MSHP - 2016 Health Policy Research

Children's Hospital of Philadelphia, , Fellowship - 2016 Pediatric Hematology/Oncology

University of California San Francisco, , - 2020 Diversity, Equity, and Inclusion Champion Training

Awards and Honors

Fellow Award | 2016
Fellow Award, Bear Necessities Pediatric Cancer Foundation, 2016-2017
Bear Necessities Pediatric Cancer Foundation

Clinical Research Training Institute | 2016
Clinical Research Training Institute, American Society of Hematology, 2016-2017
American Society of Hematology

Paul Calabresi Career Development Award for Clinical Oncology (K12) | 2016
Paul Calabresi Career Development Award for Clinical Oncology (K12), Abramson Cancer Center, 2016-2018
Abramson Cancer Center

Young Investigator Award | 2016
Young Investigator Award, Alex's Lemonade Stand Foundation, 2016-2019
Alex's Lemonade Stand Foundation

Fellow to Faculty Scholar Award | 2020
Fellow to Faculty Scholar Award, American Society of Hematology, 2020-2022
American Society of Hematology
My research explores racial, ethnic, and socioeconomic disparities in access to care and outcome of leukemia and lymphoma treatment. I study access to care across the continuum of pediatric cancer from diagnosis and clinical trial enrollment through treatment and relapse to salvage therapies. My research has shown that African American children with acute lymphoblastic leukemia, acute myeloid leukemia, and mature B cell lymphoma are two times more likely to present with organ failure at the time of a new cancer diagnosis. My ongoing work investigates access to highly specialized and complex therapies such as stem cell transplant, chimeric antigen receptor T cells, and MIBG therapy.